23 May 2013
Keywords: mixed, data, impact-ii, trial, integrelin, results, cor
Article | 11 September 1995
Mixed results from the IMPACT-II trial of Cor Therapeutics' glycoprotein
IIb/IIIa receptor antagonist Integrelin were presented at the European
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 September 1995
25 September 1995
4 September 1995
© 2013 thepharmaletter.com